JP2003528096A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528096A5 JP2003528096A5 JP2001568934A JP2001568934A JP2003528096A5 JP 2003528096 A5 JP2003528096 A5 JP 2003528096A5 JP 2001568934 A JP2001568934 A JP 2001568934A JP 2001568934 A JP2001568934 A JP 2001568934A JP 2003528096 A5 JP2003528096 A5 JP 2003528096A5
- Authority
- JP
- Japan
- Prior art keywords
- decahydro
- methanone
- piperazin
- propyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Hydrogen Chemical class 0.000 description 41
- 150000001875 compounds Chemical class 0.000 description 11
- 239000002253 acid Substances 0.000 description 9
- 239000012458 free base Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 6
- 125000005605 benzo group Chemical group 0.000 description 6
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 0 BN(CC1)CCN1C(C1C(CCCC2)C2CN(CC(*)C*)C1)=O Chemical compound BN(CC1)CCN1C(C1C(CCCC2)C2CN(CC(*)C*)C1)=O 0.000 description 2
- YIFHFKIAGWFMFR-CYUUXAIJSA-N CC1=NN2C=C(C=CC2=N1)C[C@H](C)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC(=C(C=C6)F)F Chemical compound CC1=NN2C=C(C=CC2=N1)C[C@H](C)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC(=C(C=C6)F)F YIFHFKIAGWFMFR-CYUUXAIJSA-N 0.000 description 2
- MZEIROPEHDVJSM-UICHKGEESA-N CCOC1=NC=C(C=C1)C[C@H](C)CN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC(=C(C=C5)F)F Chemical compound CCOC1=NC=C(C=C1)C[C@H](C)CN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC(=C(C=C5)F)F MZEIROPEHDVJSM-UICHKGEESA-N 0.000 description 2
- RDSAUPRYZCQORM-VBSYDLGNSA-N C[C@H](CC1=CN=C(C=C1)OC)CN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC(=C(C=C5)F)F Chemical compound C[C@H](CC1=CN=C(C=C1)OC)CN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC(=C(C=C5)F)F RDSAUPRYZCQORM-VBSYDLGNSA-N 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- LSHVDMSVIBRMJS-UHFFFAOYSA-N BN(CC1)CCN1C(C1C(CCCC2)C2CNC1)=O Chemical compound BN(CC1)CCN1C(C1C(CCCC2)C2CNC1)=O LSHVDMSVIBRMJS-UHFFFAOYSA-N 0.000 description 1
- PBIJFETZVGZXDS-UHFFFAOYSA-N C1CCC2C(C1)CN(CC2C(=O)N3CCN(CC3)C4=CC=C(C=C4)[N+](=O)[O-])CCCC5=CC6=C(C=C5)OCO6 Chemical compound C1CCC2C(C1)CN(CC2C(=O)N3CCN(CC3)C4=CC=C(C=C4)[N+](=O)[O-])CCCC5=CC6=C(C=C5)OCO6 PBIJFETZVGZXDS-UHFFFAOYSA-N 0.000 description 1
- FALYLKFOGKFFCZ-PZUNEJSGSA-N C1CC[C@H]2[C@H](C1)CN(C[C@H]2C(=O)N3CCN(CC3)C4=CC(=C(C=C4)F)F)CCCC5=CC6=C(C=C5)OCO6 Chemical compound C1CC[C@H]2[C@H](C1)CN(C[C@H]2C(=O)N3CCN(CC3)C4=CC(=C(C=C4)F)F)CCCC5=CC6=C(C=C5)OCO6 FALYLKFOGKFFCZ-PZUNEJSGSA-N 0.000 description 1
- KNKREEACRCCPBZ-TZFWCWEWSA-N CC(=O)C1=CC(=CC(=C1)CCCN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC6=NON=C6C=C5)C(=O)C Chemical compound CC(=O)C1=CC(=CC(=C1)CCCN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC6=NON=C6C=C5)C(=O)C KNKREEACRCCPBZ-TZFWCWEWSA-N 0.000 description 1
- UKACSKJZQHGMHF-QKBZBAIHSA-N CC(C)[C@H](CC1=CC2=C(C=C1)OCO2)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC7=NON=C7C=C6 Chemical compound CC(C)[C@H](CC1=CC2=C(C=C1)OCO2)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC7=NON=C7C=C6 UKACSKJZQHGMHF-QKBZBAIHSA-N 0.000 description 1
- ZZFYFCYIPZHOSH-DMTNHVFBSA-N CC1=NC2=C(O1)C=CC(=C2)CCCN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC(=C(C=C6)F)F Chemical compound CC1=NC2=C(O1)C=CC(=C2)CCCN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC(=C(C=C6)F)F ZZFYFCYIPZHOSH-DMTNHVFBSA-N 0.000 description 1
- ORWKFKYYOVHTJR-CYUUXAIJSA-N CC1=NC2=C(O1)C=CC(=C2)C[C@H](C)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC(=C(C=C6)F)F Chemical compound CC1=NC2=C(O1)C=CC(=C2)C[C@H](C)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC(=C(C=C6)F)F ORWKFKYYOVHTJR-CYUUXAIJSA-N 0.000 description 1
- DDNQJKWULPOEKJ-CYUUXAIJSA-N CC1=NC2=C(O1)C=CC(=C2)C[C@H](C)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC7=NON=C7C=C6 Chemical compound CC1=NC2=C(O1)C=CC(=C2)C[C@H](C)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC7=NON=C7C=C6 DDNQJKWULPOEKJ-CYUUXAIJSA-N 0.000 description 1
- SCMGZLCXEWZMAF-YQXNOVQFSA-N CC1=NC2=C(O1)C=CC(=C2)C[C@H](C)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC=C(C=C6)C#N Chemical compound CC1=NC2=C(O1)C=CC(=C2)C[C@H](C)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC=C(C=C6)C#N SCMGZLCXEWZMAF-YQXNOVQFSA-N 0.000 description 1
- VHVPOXNMDWTTLR-UICHKGEESA-N CCNC1=NC=C(C=C1)C[C@H](C)CN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC(=C(C=C5)F)F Chemical compound CCNC1=NC=C(C=C1)C[C@H](C)CN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC(=C(C=C5)F)F VHVPOXNMDWTTLR-UICHKGEESA-N 0.000 description 1
- AMCUTXLZCZZZGJ-MDMAHDEASA-N CCOC1=NC=C(C=C1)C[C@H](C)CN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC=C(C=C5)C#N Chemical compound CCOC1=NC=C(C=C1)C[C@H](C)CN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC=C(C=C5)C#N AMCUTXLZCZZZGJ-MDMAHDEASA-N 0.000 description 1
- KSSRLNAVLKWQQB-NRSKXHDUSA-N COC(=O)C1=CC(=CC(=C1)CCCN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC=C(C=C5)[N+](=O)[O-])C(=O)OC Chemical compound COC(=O)C1=CC(=CC(=C1)CCCN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC=C(C=C5)[N+](=O)[O-])C(=O)OC KSSRLNAVLKWQQB-NRSKXHDUSA-N 0.000 description 1
- NVRFWMASOFUUJK-IVTVSAFSSA-N C[C@@H](CC1=CC2=C(C=C1)OC=N2)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC(=C(C=C6)F)F Chemical compound C[C@@H](CC1=CC2=C(C=C1)OC=N2)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC(=C(C=C6)F)F NVRFWMASOFUUJK-IVTVSAFSSA-N 0.000 description 1
- PXKLEJCHPGUZTI-IVTVSAFSSA-N C[C@@H](CC1=CC2=C(C=C1)OCO2)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC7=NON=C7C=C6 Chemical compound C[C@@H](CC1=CC2=C(C=C1)OCO2)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC7=NON=C7C=C6 PXKLEJCHPGUZTI-IVTVSAFSSA-N 0.000 description 1
- CNPQNESZCIIZNH-MKLBEGSSSA-N C[C@@H](CC1=CC2=C(C=C1)ONO2)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC=C(C=C6)C#N Chemical compound C[C@@H](CC1=CC2=C(C=C1)ONO2)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC=C(C=C6)C#N CNPQNESZCIIZNH-MKLBEGSSSA-N 0.000 description 1
- WJLWPOMHOMKGEB-MDMAHDEASA-N C[C@@H](CC1=CC2=NC=CN=C2C=C1)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC=C(C=C6)C#N Chemical compound C[C@@H](CC1=CC2=NC=CN=C2C=C1)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC=C(C=C6)C#N WJLWPOMHOMKGEB-MDMAHDEASA-N 0.000 description 1
- FXULLNLFEFAYPW-UHRQBARKSA-N C[C@@H](CC1=CC2=NC=CN=C2C=C1)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=NC7=NON=C7C=C6 Chemical compound C[C@@H](CC1=CC2=NC=CN=C2C=C1)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=NC7=NON=C7C=C6 FXULLNLFEFAYPW-UHRQBARKSA-N 0.000 description 1
- RGQCQEXWUZOUCH-MKLBEGSSSA-N C[C@@H](CC1=CC2=NSN=C2C=C1)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC=C(C=C6)C#N Chemical compound C[C@@H](CC1=CC2=NSN=C2C=C1)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC=C(C=C6)C#N RGQCQEXWUZOUCH-MKLBEGSSSA-N 0.000 description 1
- BDCQIKPPJIYFGF-XDWXJERXSA-N C[C@@H](CC1=CC2=NSN=C2C=C1)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=NC=C(C=C6)C#N Chemical compound C[C@@H](CC1=CC2=NSN=C2C=C1)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=NC=C(C=C6)C#N BDCQIKPPJIYFGF-XDWXJERXSA-N 0.000 description 1
- PSPZLMYZALLDRV-UICHKGEESA-N C[C@@H](CC1=CN2C=CN=C2C=C1)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC7=NON=C7C=C6 Chemical compound C[C@@H](CC1=CN2C=CN=C2C=C1)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC7=NON=C7C=C6 PSPZLMYZALLDRV-UICHKGEESA-N 0.000 description 1
- TWXRBKVFDJGPSS-IVTVSAFSSA-N C[C@@H](CC1=CN=C(C=C1)OC)CN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC6=NON=C6C=C5 Chemical compound C[C@@H](CC1=CN=C(C=C1)OC)CN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC6=NON=C6C=C5 TWXRBKVFDJGPSS-IVTVSAFSSA-N 0.000 description 1
- YBLVKGXHBMIOAB-IPGTZRFSSA-N C[C@@H](CC1=CN=C(C=C1)OC)CN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC=C(C=C5)C#N Chemical compound C[C@@H](CC1=CN=C(C=C1)OC)CN2C[C@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC=C(C=C5)C#N YBLVKGXHBMIOAB-IPGTZRFSSA-N 0.000 description 1
- RGSBOQCPAPABQT-VBSYDLGNSA-N C[C@H](CC1=CC2=C(C=C1)OC=N2)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC7=NON=C7C=C6 Chemical compound C[C@H](CC1=CC2=C(C=C1)OC=N2)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC7=NON=C7C=C6 RGSBOQCPAPABQT-VBSYDLGNSA-N 0.000 description 1
- KUHJMKMRUIRJSL-VBSYDLGNSA-N C[C@H](CC1=CN2C(=NC=N2)C=C1)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC(=C(C=C6)F)F Chemical compound C[C@H](CC1=CN2C(=NC=N2)C=C1)CN3C[C@H]4CCCC[C@@H]4[C@@H](C3)C(=O)N5CCN(CC5)C6=CC(=C(C=C6)F)F KUHJMKMRUIRJSL-VBSYDLGNSA-N 0.000 description 1
- VXLCNTLWWUDBSO-UHFFFAOYSA-N Ethiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC)NC2=C1 VXLCNTLWWUDBSO-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 241001275899 Salta Species 0.000 description 1
- ZUKSFLFVDPKYES-DAANFHMWSA-N [(4s,4as,8ar)-2-[(2s)-2-methyl-3-quinoxalin-6-ylpropyl]-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinolin-4-yl]-[4-(3,4-difluorophenyl)piperazin-1-yl]methanone Chemical compound O=C([C@H]1[C@H]2CCCC[C@H]2CN(C1)C[C@@H](C)CC=1C=C2N=CC=NC2=CC=1)N(CC1)CCN1C1=CC=C(F)C(F)=C1 ZUKSFLFVDPKYES-DAANFHMWSA-N 0.000 description 1
- RDSAUPRYZCQORM-BJTUFNSYSA-N [(4s,4as,8ar)-2-[(2s)-3-(6-methoxypyridin-3-yl)-2-methylpropyl]-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinolin-4-yl]-[4-(3,4-difluorophenyl)piperazin-1-yl]methanone Chemical compound C1=NC(OC)=CC=C1C[C@H](C)CN1C[C@@H](C(=O)N2CCN(CC2)C=2C=C(F)C(F)=CC=2)[C@H]2CCCC[C@H]2C1 RDSAUPRYZCQORM-BJTUFNSYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0007108.4A GB0007108D0 (en) | 2000-03-23 | 2000-03-23 | Organic compounds |
| GB0007108.4 | 2000-03-23 | ||
| PCT/EP2001/003211 WO2001070731A1 (en) | 2000-03-23 | 2001-03-21 | Decahydro-isoquinolines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003528096A JP2003528096A (ja) | 2003-09-24 |
| JP2003528096A5 true JP2003528096A5 (enExample) | 2007-12-27 |
| JP4118565B2 JP4118565B2 (ja) | 2008-07-16 |
Family
ID=9888307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001568934A Expired - Fee Related JP4118565B2 (ja) | 2000-03-23 | 2001-03-21 | デカヒドロ−イソキノリン |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6635647B2 (enExample) |
| EP (1) | EP1268466B1 (enExample) |
| JP (1) | JP4118565B2 (enExample) |
| AR (1) | AR029821A1 (enExample) |
| AT (1) | ATE298332T1 (enExample) |
| AU (1) | AU2001239310A1 (enExample) |
| CA (1) | CA2402751C (enExample) |
| CO (1) | CO5271675A1 (enExample) |
| DE (1) | DE60111621T2 (enExample) |
| DK (1) | DK1268466T3 (enExample) |
| ES (1) | ES2243462T3 (enExample) |
| GB (1) | GB0007108D0 (enExample) |
| PE (1) | PE20011114A1 (enExample) |
| PT (1) | PT1268466E (enExample) |
| WO (1) | WO2001070731A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| EP1979323A1 (en) * | 2006-01-30 | 2008-10-15 | Speedel Experimenta AG | Process for the stereoselective preparation of alcohols from alpha, beta-insaturated compounds |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| SI2203439T1 (sl) | 2007-09-14 | 2011-05-31 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni |
| BRPI0817101A2 (pt) | 2007-09-14 | 2017-05-09 | Addex Pharmaceuticals Sa | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas |
| ES2439291T3 (es) | 2008-09-02 | 2014-01-22 | Janssen Pharmaceuticals, Inc. | Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos |
| ES2401691T3 (es) | 2008-11-28 | 2013-04-23 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato |
| ES2440001T3 (es) | 2009-05-12 | 2014-01-27 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| SG176018A1 (en) | 2009-05-12 | 2011-12-29 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| WO2011082271A2 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted triazolo-pyrimidine compounds |
| CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| ES2552455T3 (es) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| CN103298809B (zh) | 2010-11-08 | 2016-08-31 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| IL279202B2 (en) | 2014-01-21 | 2023-09-01 | Janssen Pharmaceutica Nv | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use |
| US10537573B2 (en) | 2014-01-21 | 2020-01-21 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| KR20200035035A (ko) | 2017-07-31 | 2020-04-01 | 노파르티스 아게 | 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도 |
| BR112020005489A2 (pt) | 2017-09-22 | 2020-09-24 | Jubilant Epipad Llc, | composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer |
| CN111225915B (zh) | 2017-10-18 | 2023-03-07 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的咪唑并吡啶化合物 |
| EP3707135A1 (en) | 2017-11-06 | 2020-09-16 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
| IL274762B2 (en) | 2017-11-24 | 2023-10-01 | Jubilant Episcribe Llc | Novel heterocyclic compounds as prmt5 inhibitors |
| EP3765453A1 (en) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1070054A1 (en) * | 1998-04-08 | 2001-01-24 | Takeda Chemical Industries, Ltd. | Amine compounds, their production and their use as somatostatin receptor antagonists or agonists |
-
2000
- 2000-03-23 GB GBGB0007108.4A patent/GB0007108D0/en not_active Ceased
-
2001
- 2001-03-21 ES ES01913896T patent/ES2243462T3/es not_active Expired - Lifetime
- 2001-03-21 AU AU2001239310A patent/AU2001239310A1/en not_active Abandoned
- 2001-03-21 AT AT01913896T patent/ATE298332T1/de not_active IP Right Cessation
- 2001-03-21 AR ARP010101320A patent/AR029821A1/es unknown
- 2001-03-21 WO PCT/EP2001/003211 patent/WO2001070731A1/en not_active Ceased
- 2001-03-21 PE PE2001000262A patent/PE20011114A1/es not_active Application Discontinuation
- 2001-03-21 DE DE60111621T patent/DE60111621T2/de not_active Expired - Lifetime
- 2001-03-21 PT PT01913896T patent/PT1268466E/pt unknown
- 2001-03-21 CO CO01022539A patent/CO5271675A1/es not_active Application Discontinuation
- 2001-03-21 JP JP2001568934A patent/JP4118565B2/ja not_active Expired - Fee Related
- 2001-03-21 CA CA002402751A patent/CA2402751C/en not_active Expired - Fee Related
- 2001-03-21 EP EP01913896A patent/EP1268466B1/en not_active Expired - Lifetime
- 2001-03-21 DK DK01913896T patent/DK1268466T3/da active
- 2001-03-21 US US10/221,983 patent/US6635647B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003528096A5 (enExample) | ||
| JP5767393B2 (ja) | 新規二環式ピリジノン | |
| JP2019521090A (ja) | ピルビン酸キナーゼ（ｐｋｒ）活性化剤としてのピロロピロール組成物 | |
| JP4118565B2 (ja) | デカヒドロ−イソキノリン | |
| TW201010977A (en) | Amide compound | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| RU2007147413A (ru) | Аминопиперидинхинолины и их азаизостерические аналоги с антибактериальной активностью | |
| HRP20160036T1 (hr) | Određeni kemijski entiteti, priprave i metode koji sadrže imidazopirimidin | |
| WO2015173181A1 (en) | Compounds for treating spinal muscular atrophy | |
| RU2015124917A (ru) | Новые бициклические фенилпиридины/пиразины для лечения рака | |
| CN106103416A (zh) | 作为trpm8拮抗剂的氮杂螺衍生物 | |
| CN102686565A (zh) | 丙型肝炎病毒抑制剂 | |
| WO2013117645A1 (en) | Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases | |
| RU2009120229A (ru) | Производные хинуклидинола в качестве антагонистов мускариновых рецепторов | |
| CN1939910A (zh) | 氨基嘧啶类化合物及其盐和其制备方法与药物用途 | |
| CN115996926A (zh) | 作为雄激素受体调节剂的吲哚化合物 | |
| BR112016024455B1 (pt) | Composto heterocíclico bicíclico ou tricíclico | |
| CN1675210A (zh) | 用作磷酸二酯酶抑制剂的取代2,4－二氢－吡咯并[3,4－b]喹啉－9－酮衍生物 | |
| CA2925743C (en) | Novel bicyclic pyridinones as gamma-secretase modulators | |
| EP4634183A1 (en) | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions | |
| WO2024130065A1 (en) | Substituted dihydropyrrolo[3, 4-d]pyrimidine compounds and their use in treating medical conditions | |
| RU2007112675A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ТРИАЗОЛО[1,5-d]БЕНЗОДИАЗЕПИНА ДЛЯ ЛЕЧЕНИЯ КОГНИТИВНЫХ РАССТРОЙСТВ | |
| JP2008508359A5 (enExample) | ||
| JP2017081908A (ja) | 医薬組成物 | |
| CN1910190A (zh) | 环氨基取代的噻吩并嘧啶和噻吩并吡啶衍生物 |